antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2023-68-7-8-70-77antibiotics-1065Research ArticleОБЗОРЫREVIEWSОценка эффективности новых неспецифических средств медицинской защиты в отношении аренавирусных геморрагических лихорадоThe Estimation of Efficacy of Nonspecific Medications Against Hemorrhagic Fevers Caused by Arenaviruseshttps://orcid.org/0000-0002-1817-0126СизиковаТ. Е.SizikovaТ. Е.

Сизикова Татьяна Евгеньевна — к. б. н., старший научный сотрудник

Сергиев Посад

Tatiana E. Sizikova — Ph. D. in Biology

Sergiev Posad

https://orcid.org/0000-0002-6552-4599ЛебедевВ. Н.LebedevV. N.

Лебедев Виталий Николаевич — д. б. н., профессор, ведущий научный сотрудник

Сергиев Посад

Vitaliy N. Lebedev — D. Sc. in Biology, Professor, Leading Researcher

Sergiev Posad

https://orcid.org/0000-0002-6742-3919БорисевичС. В.BorisevichS. V.

Борисевич Сергей Владимирович — д. б. н., профессор, академик РАН, начальник института

Сергиев Посад

Sergey V. Borisevich — D. Sc. in Biology, Professor, Academician of the Russian Academy of Sciences, Head of the Institute

Sergiev Posad

48cnii@mil.ruФГБУ «48 Центральный научно-исследовательский институт» Минобороны РоссииРоссия48 Central Scientific Research Institute of the Ministry of Defence of the Russian FederationRussian Federation202325122023687-87077Copyright © Сизикова Т.Е., Лебедев В.Н., Борисевич С.В., 20232023Сизикова Т.Е., Лебедев В.Н., Борисевич С.В.Sizikova Т.Е., Lebedev V.N., Borisevich S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/1065

Представлен анализ исследований по оценке эффективности новых неспецифических средств медицинской защиты (СМЗ) в отношении аренавирусных геморрагических лихорадок. Рассмотрены возможные мишени для неспецифических СМЗ, классы изученных противовирусных препаратов, методы доклинического изучения противовирусных препаратов in vitro и на лабораторных животных, а также перспективы их использования в практике здравоохранения в настоящее время. Показано, что уровень разработки неспецифических СМЗ в отношении аренавирусных геморрагических лихорадок существенно уступает таковому для филовирусных инфекций. В качестве наиболее эффективного неспецифического СМЗ в отношении аренавирусных геморрагических лихорадок в настоящее время следует рассматривать фавипиравир.

The article presents an analysis of studies assessing the effectiveness of new nonspecific medications against hemorrhagic fevers caused by arenaviruses. The possible targets for nonspecific medications, classes of researched antiviral preparations, methods of preclinical investigation of antiviral preparations in vitro and on laboratory animals, as well as prospects for their use in healthcare at present are considered. It has been shown that the level of development of nonspecific medications against hemorrhagic fevers caused by arenaviruses is significantly inferior to those against filovirus infections. Favipiravir should currently be considered as the most effective nonspecific medication against hemorrhagic fevers caused by arenaviruses.

аренавирусные геморрагические лихорадкивирус Хунинвирус Лассамедицинские средства защитыфавипиравирhemorrhagic fevers caused by arenavirusesJunin virusLassa virustherapeuticfavipiravirReferencesPeters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee K.T.Jr., Barrera Oro J.G. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol. 1987; 134: 5–68. doi: 10.1007/978-3-642-71726-0_2.Peters C.J., Jahrling P.B., Liu C.T., Kenyon R.H., McKee K.T.Jr., Barrera Oro J.G. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol. 1987; 134: 5–68. doi: 10.1007/978-3-642-71726-0_2.Radoshitzky S.R., Bao Y., Buchmeier M.J., Charrel R.N., Clawson A., Clegg C., DeRisi J.L., Gonzales J.P., Kuhn J.H., Lukashevich I.S., Peters C.J., Romanowski V., Salvato M.S., Stanglein M.D., de la Torre J.C. Past, present and future of arenavirus taxonomy. Arch Virol. 2015; 160 (7): 1851–1874. doi: 10.1007/s00705-015-2418-y.Radoshitzky S.R., Bao Y., Buchmeier M.J., Charrel R.N., Clawson A., Clegg C., DeRisi J.L., Gonzales J.P., Kuhn J.H., Lukashevich I.S., Peters C.J., Romanowski V., Salvato M.S., Stanglein M.D., de la Torre J.C. Past, present and future of arenavirus taxonomy. Arch Virol. 2015; 160 (7): 1851–1874. doi: 10.1007/s00705-015-2418-y.Charrel R.N., de Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res. 2003; 57 (1–2): 89100. doi: 10.1016/s0166-3542(02)00202-4.Charrel R.N., de Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res. 2003; 57 (1–2): 89100. doi: 10.1016/s0166-3542(02)00202-4.Briese T., Paweska J.T., McMullan L.K., Hutchison S.K., Street C., Palacios G., Khristova M.L., Weyer J., Swanepoel R., Egholm M., Nichol S.T., Lipkin W.I. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 2009; 5 (5): 1–8. doi: 10.1371/journal.ppat.1000455.Briese T., Paweska J.T., McMullan L.K., Hutchison S.K., Street C., Palacios G., Khristova M.L., Weyer J., Swanepoel R., Egholm M., Nichol S.T., Lipkin W.I. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 2009; 5 (5): 1–8. doi: 10.1371/journal.ppat.1000455.Delgado S., Erickson B.R., Agudo R., Blair P.J., Vallejo E., Albariño C.G., Vargas J., Comer J.A., Rollin P.E., Ksiazek T.G., Olson J.G., Nichol S.T. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 2008; 4 (4): 1–6. doi: 10.1371/journal.ppat.1000047.Delgado S., Erickson B.R., Agudo R., Blair P.J., Vallejo E., Albariño C.G., Vargas J., Comer J.A., Rollin P.E., Ksiazek T.G., Olson J.G., Nichol S.T. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 2008; 4 (4): 1–6. doi: 10.1371/journal.ppat.1000047.Emia D.A., Maiztegui J.I. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 1994; 23(1): 23–31. doi: 10.1016/0166-3542(94)90030-2.Emia D.A., Maiztegui J.I. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 1994; 23(1): 23–31. doi: 10.1016/0166-3542(94)90030-2.Gonsales J.P., Bowen M.D., Nichol S.T., Rico-Hesse R. Genetic characterization and phylogeny of Sabia virus, an emergent pathogen in Brazil. Virology. 1996; 221 (2): 318–324. doi: 10.1006/viro.1996.0381.Gonsales J.P., Bowen M.D., Nichol S.T., Rico-Hesse R. Genetic characterization and phylogeny of Sabia virus, an emergent pathogen in Brazil. Virology. 1996; 221 (2): 318–324. doi: 10.1006/viro.1996.0381.Kranzusch P.J., Schenk A.D., Rahmeh A.A., Radoshitzky S.R., Bavari S., Walz T., Whelan S.P. Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci USA. 2010; 107 (46): 20069–74. doi: 10.1073/ pnas.1007152107.Kranzusch P.J., Schenk A.D., Rahmeh A.A., Radoshitzky S.R., Bavari S., Walz T., Whelan S.P. Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci USA. 2010; 107 (46): 20069–74. doi: 10.1073/ pnas.1007152107.Salas R., de Manzione N., Tesh R. et al. Venezuelan hemorrhagic fever. Lancet. 1991; 338: (8774): 1033–1036. doi: 10.1016/0140-6736(91)91899-6.Salas R., de Manzione N., Tesh R. et al. Venezuelan hemorrhagic fever. Lancet. 1991; 338: (8774): 1033–1036. doi: 10.1016/0140-6736(91)91899-6.McCormick J.B., Fisher-Hoch S.P. Lassa fever. Curr Top Microbiol Immunol. 2002; 262: 75–109. doi: 10.1007/978-3-642-56029-3_4.McCormick J.B., Fisher-Hoch S.P. Lassa fever. Curr Top Microbiol Immunol. 2002; 262: 75–109. doi: 10.1007/978-3-642-56029-3_4.Radoshitzky S.R., Kuhn J.H., de Kok-Mercado F., Jahrling P.B., Bavari S. Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opin Drug Discov. 2012; 7 (7): 613–32. doi: 10.1517/17460441.2012.687719.Radoshitzky S.R., Kuhn J.H., de Kok-Mercado F., Jahrling P.B., Bavari S. Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opin Drug Discov. 2012; 7 (7): 613–32. doi: 10.1517/17460441.2012.687719.Emia D.A., Barrera O.J.G. Junin virus vaccines /In: Oldstone M.B.A. Arenaviruses II The Molecular pathogenesis of arenavirus infections. Springer Verlag, Berlin, 2002.Emia D.A., Barrera O.J.G. Junin virus vaccines /In: Oldstone M.B.A. Arenaviruses II The Molecular pathogenesis of arenavirus infections. Springer Verlag, Berlin, 2002.Barry M., Russi M., Armstrong L., Geller D., Tesh R., Dembry L., Gonzalez J.P., Khan A.S., Peters C.J. Brief report: treatment of a laboratory-acquired Sabiá virus infection. N. Engl. J. Med. 1995; 333(5): 294–296. doi: 10.1056/NEJM199508033330505.Barry M., Russi M., Armstrong L., Geller D., Tesh R., Dembry L., Gonzalez J.P., Khan A.S., Peters C.J. Brief report: treatment of a laboratory-acquired Sabiá virus infection. N. Engl. J. Med. 1995; 333(5): 294–296. doi: 10.1056/NEJM199508033330505.Emia D.A., Briggiler A.M., Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008; 78 (1): 132–9. doi: 10.1016/j.antiviral.2007.10.010.Emia D.A., Briggiler A.M., Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008; 78 (1): 132–9. doi: 10.1016/j.antiviral.2007.10.010.Khan S.H., Goba A., Chu M., Roth C., Healing T., Marx A., Fair J., Guttieri M.C., Ferro P., Imes T., Monagin C., Garry R.F., Bausch D.G. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 2008; 78 (1): 103–15. doi: 10.1016/j.antiviral.2007.11.003.Khan S.H., Goba A., Chu M., Roth C., Healing T., Marx A., Fair J., Guttieri M.C., Ferro P., Imes T., Monagin C., Garry R.F., Bausch D.G. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 2008; 78 (1): 103–15. doi: 10.1016/j.antiviral.2007.11.003.Cао W., Henry M.D., Borrow P., Yamada H., Elder J.H., Ravkov E.V., Nichol S.T., Compans R.W. Campbell K.P., Oldstone M.B. Identification of alphadystroglycan as a receptor for lymphocytes choriomeningitis virus and Lassa fever virus. Science. 1998: 282; 2079–2081.Cао W., Henry M.D., Borrow P., Yamada H., Elder J.H., Ravkov E.V., Nichol S.T., Compans R.W. Campbell K.P., Oldstone M.B. Identification of alphadystroglycan as a receptor for lymphocytes choriomeningitis virus and Lassa fever virus. Science. 1998: 282; 2079–2081.Shao J., Liang Y., Ly H. Human hemorrhagic fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis. Pathogens. 2015; 4 (2): 283–306. doi: 10.3390/ pathogens4020283.Shao J., Liang Y., Ly H. Human hemorrhagic fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis. Pathogens. 2015; 4 (2): 283–306. doi: 10.3390/ pathogens4020283.Helguera G., Jemielity S., Abraham J., Cordo S.M., Martinez M.G., Rodríguez J.A., Bregni C., Wang J.J., Farzan M., Penichet M.L., Candurra N.A., Choe H. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic fever arenaviruses. J Virol. 2012; 86 (7): 4024–4028. doi: 10.1128/JVI.06397-11.Helguera G., Jemielity S., Abraham J., Cordo S.M., Martinez M.G., Rodríguez J.A., Bregni C., Wang J.J., Farzan M., Penichet M.L., Candurra N.A., Choe H. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic fever arenaviruses. J Virol. 2012; 86 (7): 4024–4028. doi: 10.1128/JVI.06397-11.Radoshitzky S.R.,Kuhn J.H., Spiropoulo C.F., Albarino G.G., Nguyen D.P., Salazar-Bravo J., Dortman T., Lee A.S., Wang E., Ross S.R. Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. PNAS USA. 2008; 105: 2664–2669. doi: 10.1073/pnas. 0709254105.Radoshitzky S.R.,Kuhn J.H., Spiropoulo C.F., Albarino G.G., Nguyen D.P., Salazar-Bravo J., Dortman T., Lee A.S., Wang E., Ross S.R. Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. PNAS USA. 2008; 105: 2664–2669. doi: 10.1073/pnas. 0709254105.Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117 (3): 285–297. doi: 10.1016/s0092-8674(04)00343-5.Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117 (3): 285–297. doi: 10.1016/s0092-8674(04)00343-5.Morin B., Coutard B., Lelke M., Ferron F., Kerber R., Jamal S., Frangeul A., Baronti C., Charrel R., de Lamballerie X., Vonrhein C., Lescar J., Bricogne G., Günther S., Canard B. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog. 2010; 6 (9): 1–11. doi: 10.1371/journal.ppat.1001038.Morin B., Coutard B., Lelke M., Ferron F., Kerber R., Jamal S., Frangeul A., Baronti C., Charrel R., de Lamballerie X., Vonrhein C., Lescar J., Bricogne G., Günther S., Canard B. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog. 2010; 6 (9): 1–11. doi: 10.1371/journal.ppat.1001038.Brunotte L., Kerber R., Shang W., Hauer F., Hass M., Gabriel M., Lelke M., Busch C., Stark H., Svergun D.I., Betzel C., Perbandt M., Günther S. Structure of the Lassa virus nucleoprotein revealed by X-ray crystallography, small-angle X-ray scattering, and electron microscopy. J Biol Chem. 2011; 286 (44): 38748–56. doi: 10.1074/jbc.M111.278838.Brunotte L., Kerber R., Shang W., Hauer F., Hass M., Gabriel M., Lelke M., Busch C., Stark H., Svergun D.I., Betzel C., Perbandt M., Günther S. Structure of the Lassa virus nucleoprotein revealed by X-ray crystallography, small-angle X-ray scattering, and electron microscopy. J Biol Chem. 2011; 286 (44): 38748–56. doi: 10.1074/jbc.M111.278838.Hastie K.M., Liu T., Li S., King L.B., Ngo N., Zandonatti M.A., Woods V.L.Jr., de la Torre J.C., Saphire E.O. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci USA. 2011; 108 (48): 19365–70. doi: 10.1073/pnas.1108515108.Hastie K.M., Liu T., Li S., King L.B., Ngo N., Zandonatti M.A., Woods V.L.Jr., de la Torre J.C., Saphire E.O. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci USA. 2011; 108 (48): 19365–70. doi: 10.1073/pnas.1108515108.Bolken T.C., Laquerre S., Zhang Y., Bailey T.R., Pevear D.C., Kickner S.S., Sperzel L.E., Jones K.F., Warren T.K., Lund S.A., Kirkwood-Watts D.L., King D.S., Shurtleff A.C., Guttieri M.C., Deng Y., Bleam M., Hruby D.E. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 2006; 69 (2): 86–97. doi:10.1016/ j.antiviral. 2005.10.008.Bolken T.C., Laquerre S., Zhang Y., Bailey T.R., Pevear D.C., Kickner S.S., Sperzel L.E., Jones K.F., Warren T.K., Lund S.A., Kirkwood-Watts D.L., King D.S., Shurtleff A.C., Guttieri M.C., Deng Y., Bleam M., Hruby D.E. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 2006; 69 (2): 86–97. doi:10.1016/ j.antiviral. 2005.10.008.Larson R.A., Dai D., Hosack V.T., Tan Y., Bolken T.C., Hruby D.E., Amberg S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008; 82 (21): 10768–75. doi: 10.1128/JVI.00941-08.Larson R.A., Dai D., Hosack V.T., Tan Y., Bolken T.C., Hruby D.E., Amberg S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008; 82 (21): 10768–75. doi: 10.1128/JVI.00941-08.Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B., Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem. 2008; 283 (27): 18734–42. doi: 10.1074/jbc.M802089200.Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B., Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem. 2008; 283 (27): 18734–42. doi: 10.1074/jbc.M802089200.Gowen B.B., Smee D.F., Wong M.H., Hall J.O., Jung K.H., Bailey K.W., Stevens J.R., Furuta Y., Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One. 2008; 3 (11): 1– 11. doi: 10.1371/journal.pone.0003725.Gowen B.B., Smee D.F., Wong M.H., Hall J.O., Jung K.H., Bailey K.W., Stevens J.R., Furuta Y., Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One. 2008; 3 (11): 1– 11. doi: 10.1371/journal.pone.0003725.Sepúlveda C.S., García C.C., Fascio M.L., D'Accorso N.B., Docampo Palacios M.L., Pellón R.F., Damonte E.B. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral Res. 2012; 93 (1): 16–22. doi: 10.1016/j.antiviral.2011.10.007.Sepúlveda C.S., García C.C., Fascio M.L., D'Accorso N.B., Docampo Palacios M.L., Pellón R.F., Damonte E.B. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral Res. 2012; 93 (1): 16–22. doi: 10.1016/j.antiviral.2011.10.007.García C.C., Candurra N.A., Damonte E.B. Antiviral and virucidal activities against arenaviruses of zinc-finger active compounds. Antivir Chem Chemother. 2000; 11 (3): 231–237. doi: 10.1177/095632020001100306.García C.C., Candurra N.A., Damonte E.B. Antiviral and virucidal activities against arenaviruses of zinc-finger active compounds. Antivir Chem Chemother. 2000; 11 (3): 231–237. doi: 10.1177/095632020001100306.García C.C., Candurra N.A., Damonte E.B. Mode of inactivation of arenaviruses by disulfide-based compounds. Antiviral Res. 2002; 55 (3): 437–446. doi: 10.1016/s0166-3542(02)00076-1.García C.C., Candurra N.A., Damonte E.B. Mode of inactivation of arenaviruses by disulfide-based compounds. Antiviral Res. 2002; 55 (3): 437–446. doi: 10.1016/s0166-3542(02)00076-1.García C.C., Ellenberg P.C., Artuso M.C., Scolaro L.A., Damonte E.B. Characterization of Junín virus particles inactivated by a zinc finger-reactive compound. Virus Res. 2009; 143 (1): 106–113. doi: 10.1016/j.virusres.2009.03.010.García C.C., Ellenberg P.C., Artuso M.C., Scolaro L.A., Damonte E.B. Characterization of Junín virus particles inactivated by a zinc finger-reactive compound. Virus Res. 2009; 143 (1): 106–113. doi: 10.1016/j.virusres.2009.03.010.García C.C., Topisirovic I., Djavani M., Borden K.L., Damonte E.B., Salvato M.S. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem Biophys Res Commun. 2010; 393 (4): 625–630. doi: 10.1016/j.bbrc. 2010.02.040.García C.C., Topisirovic I., Djavani M., Borden K.L., Damonte E.B., Salvato M.S. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem Biophys Res Commun. 2010; 393 (4): 625–630. doi: 10.1016/j.bbrc. 2010.02.040.García C.C., Candurra N.A., Damonte E.B. Differential inhibitory action of two azoic compounds against arenaviruses. Int J Antimicrob Agents. 2003; 21 (4): 319–324. doi: 10.1016/s0924-8579(02)00390-4.García C.C., Candurra N.A., Damonte E.B. Differential inhibitory action of two azoic compounds against arenaviruses. Int J Antimicrob Agents. 2003; 21 (4): 319–324. doi: 10.1016/s0924-8579(02)00390-4.Albiol Matanic V.C., Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int J Antimicrob Agents. 2004; 23 (4): 382–389. doi: 10.1016/j.ijantimicag.2003.07.022.Albiol Matanic V.C., Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int J Antimicrob Agents. 2004; 23 (4): 382–389. doi: 10.1016/j.ijantimicag.2003.07.022.Barradas J.S., Errea M.I., D'Accorso N.B., Sepúlveda C.S., Talarico L.B., Damonte E.B. Synthesis and antiviral activity of azoles obtained from carbohydrates. Carbohydr Res. 2008; 343 (14): 2468–2474. doi: 10.1016/j.carres.2008.06.028.Barradas J.S., Errea M.I., D'Accorso N.B., Sepúlveda C.S., Talarico L.B., Damonte E.B. Synthesis and antiviral activity of azoles obtained from carbohydrates. Carbohydr Res. 2008; 343 (14): 2468–2474. doi: 10.1016/j.carres.2008.06.028.Dunning J., Sahr F., Rojek A., Gannon F., Carson G., Idriss B., Massaquoi T., Gandi R., Joseph S., Osman H.K., Brooks T.J., Simpson A.J., Goodfellow I., Thorne L., Arias A., Merson L., Castle L., Howell-Jones R., PardinazSolis R., Hope-Gill B., Ferri M., Grove J., Kowalski M., Stepniewska K., Lang T., Whitehead J., Olliaro P., Samai M., Horby P.W. Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med. 2016; 13 (4): 1–19. doi: 10.1371/journal. pmed.1001997.Dunning J., Sahr F., Rojek A., Gannon F., Carson G., Idriss B., Massaquoi T., Gandi R., Joseph S., Osman H.K., Brooks T.J., Simpson A.J., Goodfellow I., Thorne L., Arias A., Merson L., Castle L., Howell-Jones R., PardinazSolis R., Hope-Gill B., Ferri M., Grove J., Kowalski M., Stepniewska K., Lang T., Whitehead J., Olliaro P., Samai M., Horby P.W. Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med. 2016; 13 (4): 1–19. doi: 10.1371/journal. pmed.1001997.Geisbert T.W., Lee A.C., Robbins M., Geisbert J.B., Honko A.N., Sood V., Johnson J.C., de Jong S., Tavakoli I., Judge A., Hensley L.E., Maclachlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375 (9729): 1896–905. doi: 10.1016/S0140-6736(10)60357-1.Geisbert T.W., Lee A.C., Robbins M., Geisbert J.B., Honko A.N., Sood V., Johnson J.C., de Jong S., Tavakoli I., Judge A., Hensley L.E., Maclachlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375 (9729): 1896–905. doi: 10.1016/S0140-6736(10)60357-1.Thi E.P., Mire C.E., Lee A.C.H., Geisbert J.B., Zhou J.Z., Agans K.N., Shead N.M., Deer D.J., Barbard T.R., Fenton K.A., MacLachlian I., Geisbert T.W. Lipid nanjparticle siRNA treatment of Ebola virus Makona infected primates. Nature. 2015; 521 (7552): 362–365. doi: 10.1038/nature14442.Thi E.P., Mire C.E., Lee A.C.H., Geisbert J.B., Zhou J.Z., Agans K.N., Shead N.M., Deer D.J., Barbard T.R., Fenton K.A., MacLachlian I., Geisbert T.W. Lipid nanjparticle siRNA treatment of Ebola virus Makona infected primates. Nature. 2015; 521 (7552): 362–365. doi: 10.1038/nature14442.

The authors declare that there are no conflicts of interest present.